Melissa Bersanelli

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Alessio Cortellini, Sebastiano Buti, Daniele Santini et al. · The Oncologist · 2019 · 221 citations · Full text

Life Sciences, Immunology, Oncology +17

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Alessio Cortellini, Rita Chiari, Biagio Ricciuti et al. · Clinical Lung Cancer · 2019 · 179 citations

Life Sciences, Immunology, Oncology +16

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

Melissa Bersanelli, Roberta Minari, Paola Bordi et al. · Journal of Thoracic Oncology · 2016 · 166 citations · Full text

Medicine, Medicinal Chemistry, Oncology +15

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 152 citations · Full text

Medicine, Immunology, Oncology +17